Comparison of the acute pulmonary vasodilating effect of beraprost sodium and nitric oxide in congenital heart disease - Thailand multicenter study

Circulation Journal

Volumn 69, Issue 1, 2005, Pages 61-64

  Durongpisitkul, Kritvikrom ^a   Laoprasitiporn, Duangmanee ^a   Layangool, Thanarat ^b   Sittiwankul, Rekwan ^c   Panamonta, Mannat ^d   Mokrapong, Pirapat ^e  

^a MAHIDOL UNIVERSITY   (Thailand)

^b QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^c Faculty of Medicine Chiang Mai University   (Thailand)

^d KHON KAEN UNIVERSITY   (Thailand)

^e RAJAVITHI HOSPITAL   (Thailand)

Author keywords

Beraprost sodium; Congenital heart disease; Pulmonary hypertension

Indexed keywords

BERAPROST; NITRIC OXIDE; OXYGEN;

ADOLESCENT; ADULT; ARTERY RESISTANCE; ARTICLE; BLOOD VESSEL REACTIVITY; CHILD; CLINICAL TRIAL; CONGENITAL HEART DISEASE; HEART CATHETERIZATION; HEMODYNAMIC PARAMETERS; HUMAN; INFANT; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PULMONARY HYPERTENSION; THAILAND; VASODILATATION;

ADOLESCENT; EPOPROSTENOL; FASTING; HEART CATHETERIZATION; HEART DEFECTS, CONGENITAL; HEMODYNAMIC PROCESSES; HUMANS; NITRIC OXIDE; PULMONARY CIRCULATION; THAILAND; VASODILATION; VASODILATOR AGENTS;

EID: 12344324471     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.69.61     Document Type: Article

References (25)

1. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease-long-term follow-up and prediction of outcome after surgical correction. Circulation 1987; 76: 1037-1042.
2. Lindberg L, Olsson AK, Jogi P, Jonmarker C. How common is severe pulmonary hypertension after pediatric cardiac surgery. J Thorac Cardiovasc Surg 2002; 123: 1155-1163.
3. Kidd L, Driscoll DJ, Gersony WM, Hayes CJ, Keane JF, O'Fallon WM, et al. Second Natural History study of congenital heart defects: Results of treatment of patient with ventricular septal defects. Circulation 1993; 87(Suppl I): 138-151.
4. Terai M, Niwa K, Nakazawa M, Tatsuno K, Segami K, Hamada H, et al. Mortality from congenital cardiovascular malformations in Japan, 1968 through 1997. Circ J 2002; 66: 484-488.
5. Durongpisitkul K, Soongswang J, Sriyoschati S, Ponvilawan S, Suptaweesin T, Prakanrattana U, et al. Utility of intraoperative transesophageal echocardiogram in congenital heart disease. J Med Assoc Thai 2000; 83(Suppl 2): S46-S53.
6. Kannan BR, Sivasankaran S, Tharakan JA, Titus T, Ajith Kumar VK, Francis B, et al. Long-term outcome of patients operated for large ventricular septal defects with increased pulmonary vascular resistance. Indian Mean J 2000; 55: 161-166.
7. Schaffer R, Berdat P, Stolle B, Pfammatter JP, Stocker F, Carrel T. Surgery of the complete atrioventricular canal: Relationship between age at operation, mitral regurgitation, size of the ventricular septum defect, additional malformations and early postoperative outcome. Cardiology 1999; 91: 231-235.
8. Gorenflo M, Bettendorf M, Brockmeier K, Ulmer HE. Pulmonary vasoreactivity and vasoactive mediators in children with pulmonary hypertension. Z Kardiol 2000; 89: 1000-1008.
9. Atz AM, Adatia I, Lock JE, Wessel DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999; 33: 813-819.
10. Houde C, Bohn DJ, Freedom RM, Rabinovitch M. Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J 1993; 70: 461-468.
11. Haraldsson A, Kieler-Jensen N, Nathorst-Westfel U, Bergh C, Rickste S. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 1998; 114: 780-786.
12. Opitz CF, Wensel R, Bettmann M, Schaffarczyk P, Linsclued M, Hetzer R, et al. Assessment of the vasodilator response in primary pulmonary hypertension comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24: 356-365.
13. Raffy O, Azarian R, Brenot F, Parent F, Sittson O, Petitpretz P, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996; 93: 484-488.
14. Krasuski RA, Warner JJ, Wang A, Harrison JK, Tapson VF, Bashore TM. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 2000; 36: 2004-2011.
15. Melian EB, Goa KL. A review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs 2002; 62: 107-133.
16. Ono F, Nagaya N, Kyotani S, Oya H, Nakanishi N, Miyatake K. Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension. Circ J 2003; 67: 375-378.
17. Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78: 244-247.
18. LaFrage CG, Miettinen OS. The estimation of oxygen consumption. Cardiovasc Res 1970; 4: 23-30.
19. Sugiyama S, Hirota H, Yoshida M, Takemura Y, Nakaoka Y, Oshima Y, et al. Novel insertional mutation in the bone morphogenetic protein receptor type II associated with sporadic primary pulmonary hypertension. Circ J 2004; 68: 592-594.
20. Hashimoto K, Nakamura K, Fujio H, Miyaji K, Morita H, Kusano K, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J 2004; 68: 227-231.
21. Hallioglu O, Dilber E, Celiker A. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease. Am J Cardiol 2003; 92: 1007-1009.
22. Ichida F, Uese K, Hashimoto I, Hamamichi Y, Tsubata S, Fukahara K, et al. Acute effect of oral prostacyclin and inhaled nitric oxide on pulmonary hypertension in children. J Cardiol 1997; 29: 217-224.
23. Ichida F, Uese KI, Tsubata SI, Hashimoto I, Hamamichi Y, Fukahara K, et al. Beneficial effect of an oral analog of prostacyclin on pulmonary hypertension secondary to congenital heart disease. Cardiol Young 1998; 8: 205-210.
24. Galie N, Humbert M, Vachiery JL, Vizza D, Kneussl M, Manes A, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502.
25. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.